Trial Profile
A Clinical and Mechanistic Proof of Efficacy Study With Belimumab in Chronic Immune Thrombocytopenia (ITP) Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 18 Sep 2014 New trial record